What Cipla Africa does

Cipla Africa, operating through Cipla Medpro South Africa (Pty) Limited, is the wholly-owned African subsidiary of Cipla Limited, India (BSE: 500087; NSE: CIPLA EQ). Founded in India in 1935 and active in Africa for over two decades, the entity is headquartered in Century City and manufactures and distributes pharmaceuticals across 24 therapy areas — including HIV, oncology, respiratory, cardiology, dermatology, and infectious diseases — through GMP-certified facilities in Durban and Johannesburg (South Africa) and Kampala (Uganda). It holds regulatory approvals from SAHPRA, WHO, and FDA, and supplies the South African National ARV tender alongside private pharmacy distribution, over-the-counter products (post-Actor Pharma acquisition), biosimilars (via Alvotech partnership), and chronic medicine dispensing through the CCMDD programme and Sha'p Left nurse surgery network.

The business operates an enterprise field-sales go-to-market motion anchored on government tenders, B2B pharmacy distribution, and community-based primary healthcare access points. Pricing is largely transaction/unit-based with multi-year government tender contracts and confidential negotiated pricing; ARVs have been priced at less than $1 per day since 2001, while oncology, biosimilars, and specialty products (lenalidomide, cabotegravir LA for PrEP) are positioned as affordable alternatives to originator brands. Revenue streams include government ARV tender volumes, private pharmacy and OTC distribution, managed chronic medicine dispensing services, and licensing income (e.g., Gilead Remdesivir in 127 countries).

Strategic positioning has shifted in recent years from pure ARV/essential-medicine supplier toward a diversified specialty pharma platform: acquisitions of Mirren (2018) and Actor Pharma (2023); pan-African expansion into Ghana, Kenya, Morocco, and Egypt under the 'Africa for Africa' strategy; biosimilar and long-acting injectable pipeline build-out; and entry into advanced therapies via the 2026 CAR-T Cell Therapy Africa Initiative. Sub-brands include Sha'p Left, Ajuga, Miles for Smiles, Bronki Boosters, Live2Love, and Saving Memories, reflecting investment in patient education and community health alongside core pharmaceutical revenue.

Name

Cipla Africa

Legal name

Cipla Medpro South Africa (Pty) Limited

Website

https://cipla.africa

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

251–500 employees

Short description

Cipla Africa, the African subsidiary of Cipla Limited (India), manufactures and distributes pharmaceuticals across 24 therapy areas from GMP-certified facilities in South Africa and Uganda, supplying the South African National ARV tender, private pharmacies, and community primary care networks.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

akta.pro secondary industries

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), Specialty Care Pharmaceuticals (HLAIAAAB), Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

Keywords

• Pharmaceutical manufacturing
• Antiretroviral medications
• Generic medicines
• Biosimilar therapeutics
• Primary healthcare services

Headquarters

HQ city

Century City

HQ country

United States

HQ region

North America

Offices15 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Marketing or Sales, Personnel

Revenue model

1. Government Healthcare Tenders: Cipla South Africa is the third largest pharmaceutical manufacturer serving the South African government ARV tender, supplying antiretroviral medications to public healthcare facilities through competitive tender processes.
2. Private Healthcare and Pharmacy Distribution: Distribution of prescription pharmaceuticals, biosimilars, and over-the-counter medicines through pharmacy chains and private healthcare providers.
3. Chronic Medicine Distribution Services: CCMDD pick-up point services managed through Sha'p Left nurse surgeries, providing medication access in underserved communities.
4. Acquisition of Actor Pharma: Acquisition strengthens OTC and generic medicine portfolio with established consumer brands in Women's health, Nasal, Cough & Cold, and Baby & Child categories. Actor Pharma delivered R234 million revenue in FY23.

Pricing tiers

Go-to-market motion1 record

Distribution channels6 records

Marketing channels7 records

Core offering

Cipla Africa manufactures and distributes affordable generic and specialty pharmaceuticals across 24 therapeutic areas, anchored by antiretroviral (ARV) medications, oncology treatments, biosimilars, and consumer health products. The company supplies the South African government's National ARV tender, distributes through pharmacy chains, and delivers direct community primary healthcare through the Sha'p Left nurse surgery network and CCMDD chronic medicine pick-up points. Licensed manufacturing partnerships (Gilead for remdesivir, MPP/ViiV for cabotegravir LA, Alvotech for biosimilars) extend its reach across more than 90 countries.

Product overview

Cipla Africa operates as a pharmaceutical company with a diverse product portfolio spanning prescription drugs, OTC products, biosimilars, and digital health solutions. The core offering includes antiretroviral medications (Reydin triple-combination, dual therapy ARVs, 4-in-1 paediatric ARVs, Cabotegravir LA for PrEP) for HIV management, oncology treatments (Lenalidomide), respiratory products, and biosimilars for auto-immune diseases and cancer. The company expanded through acquisition of Actor Pharma's OTC portfolio. Complementing pharmaceutical products are digital health initiatives including the Live2Love HIV education mobile game, Bronki Boosters asthma gamification campaign, Saving Memories Alzheimer's awareness, and KardioMD telehealth platform. Community healthcare services include Sha'p Left nurse surgeries providing primary care access, CCMDD chronic medicine pick-up points, COVID-19 testing units, and Cipla Foundation initiatives (Ajuga ECD, Miles for Smiles cleft surgeries). Sustainability efforts include electronic product information via QR codes and asthma inhaler recycling.

Differentiator

Problem solved

Functional benefit

Brands

• Sha'p Left: Patient-centred, population-focused, cost-aware, nurse-driven primary healthcare service providing accessible, quality, affordable care in local communities through nurse surgeries
• Ajuga
• Miles for Smiles
• Bronki Boosters
• Live2Love
• Saving Memories
• KardioMD

Products and services

• Dual Therapy ARVs (dolutegravir/lamivudine and dolutegravir/rilpivirine) Fixed-dose dual therapy antiretrovirals (dolutegravir/lamivudine and dolutegravir/rilpivirine) for HIV treatment. First dual therapy ARVs available in South Africa, reducing pill burden and side effects.
• 4-in-1 Paediatric ARV Treatment Sweet-tasting, heat-stable 4-in-1 fixed-dose combination of abacavir, lamivudine, lopinavir, and ritonavir developed with DNDi for infants and young children with HIV. Granule-filled capsules easy to administer.
• Lenalidomide Immunomodulatory drug for multiple myeloma and myelodysplastic syndromes. Registered in all strengths (5/10/15/20 mg) by SAHPRA, bringing affordable cancer treatment to South Africa.
• Remdesivir Antiviral medicine for severe COVID-19 treatment, manufactured under license from Gilead Sciences for distribution in 127 countries including South Africa.
• Cabotegravir LA for PrEP Long-acting injectable antiretroviral for HIV pre-exposure prophylaxis. Manufactured under MPP-ViiV Healthcare voluntary licensing agreement for 90 countries including sub-Saharan Africa. First and only long-acting injectable ARV for HIV prevention approved in US, Australia, Zimbabwe, South Africa and Malawi.
• Reydin (Triple-Combination ARV) Triple-combination antiretroviral treatment comprising tenofovir (TDF), lamivudine (3TC) and dolutegravir (DTG). Awarded share of South African Government's National ARV tender for TEE and TLD.
• Actor Pharma OTC Portfolio OTC and generic medicines acquired through Actor Pharma acquisition. Includes consumer brands in Women's health, Nasal, Cough & Cold, and Baby & Child categories. Fifth largest privately owned OTC player in South African private market.
• Biosimilars Portfolio (with Alvotech) Portfolio of biosimilar medicines developed in partnership with Alvotech, including products for oncology (2) and auto-immune diseases (3). Aims to increase access to biologic treatments at lower costs.
• Sha'p Left Nurse Surgeries Patient-centred, nurse-driven primary healthcare service providing accessible, quality, affordable care in local communities. 15 nurse surgeries located in South African communities (Worcester, Bellville, Verulam, Tembisa, Soshanguve, Senaoane, Rustenberg, KwaNyuswa, Grabouw, Dunoon, Mfuleni, and others).
• KardioMD Telehealth Platform Telehealth solution launched in partnership with BrandMed and Momentum Health Solutions. HPCSA and POPIA-compliant platform enabling remote patient-doctor consultations.
• CCMDD Pick-up Points Central Chronic Medicines Dispensing and Distribution service. 50+ chronic medicine pick-up points across South Africa enabling stable patients to collect medication conveniently, reducing congestion at state facilities.
• Asthma Inhaler Recycling Programme Environmental sustainability programme allowing patients to return used asthma inhalers to pharmacies for proper disposal and recycling. Plastic components repurposed into functional community items.

Quantifiable outcome

• Over 7.5 million South Africans living with HIV have access to affordable ARV treatment
• +5 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

14 partnerships are on record, tiered core and minor.

• Mind MatterscoreStrategic or Co-development Partner · 1 June 2025Cipla partnered with Mind Matters, a pioneering summit focusing on Mental Wellbeing 2.0, launching at the inaugural Thrive by WHX event on September 4, 2025 at Cape Town International Convention Centre. The collaboration aligns Cipla's 'Caring for Life' ethos with Mind Matters' vision of empowering individuals through mental resilience, neuroscience and holistic wellness. Expected attendance of 1500 participants.
• Medicines Patent Pool (MPP) / ViiV HealthcarecoreStrategic or Co-development Partner · 1 March 2023MPP signed sublicence agreement with Cipla to manufacture generic versions of cabotegravir long-acting for HIV pre-exposure prophylaxis (PrEP) in 90 countries. Cipla will manufacture in India with plans to manufacture in South Africa. This is the first long-acting injectable ARV for HIV prevention approved in US, Australia, Zimbabwe, South Africa and Malawi.
• Gilead Sciences Inc.coreOEM/ Whitelabel/ Licensing Partner · 1 January 2020Landmark agreement granting Cipla license to manufacture and distribute Remdesivir, the antiviral medicine for COVID-19 treatment, in 127 countries including South Africa and sub-Saharan Africa. Cipla has a dedicated manufacturing line at FDA-, WHO- and SAHPRA-approved production facilities.
• Operation SmilecoreStrategic or Co-development PartnerCipla Foundation's Miles for Smiles initiative partners with Operation Smile to fund corrective surgeries for people born with cleft conditions. The partnership exemplifies Cipla's corporate social responsibility philosophy of 'doing well while doing good' and represents the first corporate social investment in Ghana.
• AlvotechcoreStrategic or Co-development PartnerExclusive partnership between Alvotech and Cipla Medpro to bring five biosimilar medicines to patients in emerging markets including South Africa. Portfolio includes two oncology biosimilars and three for auto-immune diseases. Alvotech handles development and supply while Cipla manages registration and commercialization. Alvotech's CEO Mark Levick called Cipla 'an ideal commercial partner with leading presence in the South African pharmaceutical market.'
• Drugs for Neglected Diseases initiative (DNDi)coreStrategic or Co-development PartnerPartnership with not-for-profit DNDi to develop and launch the sweet-tasting, heat-stable 4-in-1 fixed-dose combination ARV for infants and young children with HIV. The formulation was approved by SAHPRA and developed with financial support from Unitaid, French Development Agency, Swiss Agency for Development and Cooperation, and other foundations.
• Western Cape Government Health DepartmentcoreStrategic or Co-development PartnerCipla Foundation partnership with Western Cape Government Health Department to support COVID-19 testing. Rolled out four screening and testing units in Overberg district with two each in Grabouw and Hermanus. Sha'p Left containers operated by clinical nurse practitioners offer low-cost healthcare services.
• Momentum Health SolutionsminorStrategic or Co-development PartnerThree-way partnership with BrandMed and Momentum Health Solutions to launch KardioMD telehealth platform during COVID-19 pandemic, providing remote healthcare consultation capabilities.
• Allergy Association of South Africa (ALLSA)minorStrategic or Co-development PartnerPartnership with asthma-related associations including ALLSA, Allergy Foundation of South Africa (AFSA), National Asthma Educational Programme (NAEP), and South African Thoracic Society (SATS) for asthma inhaler recycling initiative to ensure optimal collection and environmental compliance.
• National Department of HealthcoreStrategic or Co-development PartnerSha'p Left is part of National Department of Health Initiative to deliver chronic medication to stable patients outside state healthcare facilities. Partnership includes CCMDD unit in Kwa-Zulu Natal opened November 2017.
• CiplaQCIL (Uganda)coreStrategic or Co-development PartnerCipla Quality Chemical Industries Limited in Uganda dispatched 300,000 packs of antiretrovirals to South Africa during COVID-19 pandemic, demonstrating the Africa for Africa strategy with medication flown business class on Kenya Airways cargo planes.
• Independent Community Pharmacy Association (ICPA)minorChannel Partner/ Reseller/ DistributorCipla supports the Codeine Care Initiative being developed by ICPA for re-launch, aiming to empower pharmacists to monitor codeine-containing product purchasing behavior through a national database to address substance abuse.
• International Society of Substance Use Professionals (ISSUP)minorStrategic or Co-development PartnerPartnership with ISSUP on the Codeine Care Initiative to address codeine abuse in South Africa through better monitoring and pharmacist education.
• Serum Institute of IndiaminorStrategic or Co-development PartnerGlobal partnership with Serum Institute of India developing COVID-19 preventative vaccine. Cipla committed to bringing any successful vaccine to South Africa as quickly as possible.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Aurobindo Pharma: Indian-headquartered generic pharmaceutical manufacturer with significant ARV production and African market presence. Comparable on cost-competitive ARV supply, WHO-prequalified capacity, and emerging-market commercial model.
• Mylan (Viatris): Global generic and specialty pharmaceutical major with deep ARV franchise and strong African presence via donor-funded procurement. Comparable in HIV/infectious disease portfolio and emerging-market distribution scale, though substantially larger and broader in scope.
• Sanofi: Multinational pharmaceutical company with established African presence across vaccines, diabetes, and specialty care. Comparable as a diversified pharma serving the same African payers and patients, though with innovator-led rather than generic-led positioning.
• Teva Pharmaceutical Industries: Global generic and specialty pharmaceutical leader with presence across multiple therapeutic areas including respiratory and CNS. Comparable through overlapping respiratory and OTC franchises, though operating at much larger scale with broader geographic reach.

Direct peers

• Adcock Ingram: Major South African pharmaceutical manufacturer and distributor with a broad prescription and OTC portfolio including ARVs. Comparable through overlapping therapeutic categories, pharmacy distribution, and reliance on the South African public healthcare market.
• Aspen Pharmacare: Largest pharmaceutical manufacturer in South Africa, supplying ARVs, oncology, and specialty medicines to public and private sectors across Africa. Directly comparable as the dominant homegrown African pharma competing for the same government tenders and private pharmacy channels.

Emerging players

• Macleods Pharmaceuticals: Indian generic manufacturer with WHO-prequalified ARV and TB products widely used across African public health programs. Comparable on affordable ARV/TB product mix and emerging-market distribution focus.
• Hetero Labs: India-based pharmaceutical company with a leading position in ARV APIs and formulations, supplying African tenders. Comparable as a low-cost generic ARV competitor targeting the same donor-funded and government channels.
• Strides Pharma Science: Indian pharmaceutical company specializing in generic and soft-gel formulations with African operations. Comparable through generic ARV and OTC portfolio targeting emerging markets.

Others

• Roche: Multinational pharmaceutical and diagnostics company active in oncology and infectious disease across Africa. Comparable through oncology portfolio overlap (relevant to Cipla's biosimilar and lenalidomide ambitions) and African market footprint, though operating as a branded originator.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ciplaafrica
• YouTubeyoutube.com/user/ciplamedsa
• Facebookfacebook.com/CiplaAfrica
• LinkedInlinkedin.com/company/cipla-africa
• Instagraminstagram.com/ciplaafrica

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cipla Africa